Search
Menu
Home
HTB
2017
August
HTB
August 2017
Contents
Editorial
July/August 2017: Volume 18 Number 7/8
Special reports
i-Base 2017 appeal: we need your help….
Supplements
HIV Pipeline Report (2017)
Fit for Purpose: HIV treatment optimisation for adults and children (2017)
Conference reports
9th IAS Conference on HIV Science (IAS 2017)
HIV pipeline drugs: IAS 2017 update
Darunavir/cobicistat/FTC/TAF: 24-week interim results from phase 3 switch study
Phase 3 results with bictegravir FDC: a new integrase inhibitor combined with FTC/TAF
Doravirine/3TC/TDF compared to efavirenz/FTC/TDF as first-line ART
Continued viral suppression with long-acting cabotegravir/rilpivirine injections: 96-week LATTE-2 results
Reduced-dose darunavir is safe and effective in switch study
MK-8591: further compelling early results for both treatment and prevention
Dolutegravir outperforms lopinavir/ritonavir second-line: interim results from the DAWNING study
Preliminary results on dolutegravir use in pregnancy are reassuring
Low dose efavirenz (EFV400) can be used during pregnancy
Stillbirth rate in HIV positive women in UK/Ireland is double that of the general population
Swaziland nearly halves HIV incidence in five years
Gay men with undetectable viral load do not transmit HIV: Opposites Attract study supports U=U
HIV remission news from IAS 2017
Publications launched at IAS 2017
9th International Workshop on HIV Paediatrics, 21–22 July 2017, Paris
Chewable raltegravir tablets can be crushed and dispersed in liquid for young children
Inconsistencies between real-world data from UK and Ireland and EU recommendations for new antiretrovirals in pregnancy
Antiretrovirals
First dolutegravir-based generic FDC gets FDA tentative approval
FDA grant priority review for ibalizumab
Hepatitis coinfection
UK hepatitis A outbreak in gay men: shortages of HAV and HBV vaccines escalated to ‘national incident’
FDA approves sofosbuvir/velpatasvir/voxilaprevir (Vosevi) second-line DAA HCV treatment in the US in the US
HIV prevention and transmission
Controversial PrEP study from NHS England due to start in September
PDFs
July/August 2017: Volume 18 Number 7/8
HTB RSS
Early access
Future PrEP and new results from PURPOSE 1 and 2: does HIV exposure explain incident cases?
21 November 2024
Glasgow HIV Congress 2024
10 November 2024
Unheard: The medical practice of silencing – by Dr Rageshri Dhairyawan
9 November 2024
Bipolar disorder in people living with HIV
1 November 2024
All early access reports
Current issues
November 2024
October 2024
September 2024
Back issues
Special report
HTB news: i-Base changes during 2024
1 November 2024
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate